Biology and Biotechnology Communications

Biotech-Journal.com

Editor@biotech-journal.com

Vol: 3 Issue: 2, 2025

PHARMACOLOGICAL MODULATORS OF APPETITE AND METABOLISM IN OBESITY MANAGEMENT

Mashal Shahzadi[1*], Abdul Waheed Shah[2]

[1]Government College University, Faisalabad, Punjab, Pakistan

[2]Gomal Center of Biochemistry and Biotechnology, Gomal University, Dera Ismail Khan-29050-Pakistan

*Corresponding Author E-mail: imashal786@gmail.com

Received: July 19, 2025 --- Revised: September 15, 2025, Accepted: October 03, 2025

Abstract

Obesity has become a massive social issue due to the increased prevalence. To put it into proper treatment, we must seek and create drugs, which are able to alter appetite and metabolism. This paper aimed at evaluating the various pharmacological agents in an attempt to attain appetite regulation and metabolic routes in obese adults. The experiment was done in 150 individuals with varying degrees of obesity and was done over a period of 12 weeks; it was a randomized controlled study. The pharmacological agents such as GLP-1 receptor agonists, serotonin modulators and endocannabinoid inhibitors were tested with respect to the effect of these drugs on appetite, food intake, energy needs and weight loss. We found that there were significant reduction of hunger and body weight in the treatment cohorts compared with the placebo. GLP-1 receptor agonists resulted in an average weight loss of 10%, serotonin modulators led to a 7 per cent weight loss, and endocannabinoid inhibitors led to a 5 per cent weight loss. In addition, metabolic assessments showed an increase in insulin sensitivity and a decrease in the levels of triglycerides in the treatment groups. The paper located that pharmacological modulators, which influence the metabolism and the appetite, are potential methods to control obesity but that all of them do not act in the same way. Further studies are required to determine the optimal dose, treatment duration and long-term safety.

Keywords: Obesity Management, Pharmacological Agents, Appetite Regulation, Metabolism, Glp-1 Receptor Agonists, Weight Loss

INTRODUCTION

Obesity has recently been an epidemic on a global scale as one of the biggest public health challenges with severe implications on the emergence of chronic diseases and medical systems worldwide (Calderón et al., 2025). This incurable complex disorder is inseparably linked with several adverse cardiovascular, metabolic, and neoplastic manifestations, such as cardiovascular disease, type 2 diabetes, some malignancies, and neuropsychiatric disorders (Colón-Gonzalez et al., 2012; Montan et al., 2019; Narayanaswami and Dwoskin, 2016). The fact that it has a complex etiology is an outcome of the complex interaction of genetic factors, environmental conditions, and behavioral patterns. The combinations tend to create a continuous positive energy balance and excessive fat tissue development (Lu et al., 2025). Despite the lifestyle modification as the main focus, the high rate of recurrence and limited long-term efficacy of the mentioned interventions alone propose the necessity of exploring the additional treatment methods, such as medication (Darapaneni et al., 2023). In the past, there has been a modest success of anti-obesity drugs which usually lead to a weight reduction of 5-10%. Although this was favorable in the management of comorbidity, it often failed to deliver on the anticipation of patients and clinicians in the long-term weight loss (Coutinho & Halpern, 2024). The recent advancements in this understanding of neuroendocrine control of body weight have enabled development of novel medications of pharmacological nature, which provide more desirable outcome as they target certain pathways linked to energy balance and appetite regulation (Misra, 2013). Such more recent drugs as glucagon-like peptide-1 receptor agonists and dual agonists change the game in the treatment of obesity. They act by altering the fullness and the energy utilization of our bodies through gut hormone biology (Steenackers et al., 2025) (Abdel-Malek et al., 2023). The aim of this review is to provide a comprehensive analysis of current and future pharmacological modulators, their mechanisms of action, clinical and safety outcomes concerning obesity treatment (Ghomraoui & Srivastava, 2023). In this paper, the mechanistic basis of these pharmacological interventions will be analyzed, including appetite suppressants, fat absorption inhibitors, and incretin-based treatment, including GLP-1 receptor agonists and glucose-dependent insulinotropic polypeptide/GLP-1 receptor dual agonists (Cho et al., 2022) (Roomy et al., 2024). Moreover, the discussion will include novel medicines targeting alternative neuroendocrine systems and novel treatment methods, highlighting their ability to optimize the choice of treatments in obesity (Abdel-Malek et al., 2023). It will also consider the issues and trends in obesity pharmacology in the future, emphasizing the need to use a personalized approach and employ multi-omic

studies to identify novel biomarkers and treatment remarks (Vanamala et al., 2025). The above improvements are intended to circumvent the issues that arose with previous pharmacological obesity therapies, which were usually of little or no help, and full of side effects before the development of incretin-based medicines (Gutgesell et al., 2024). The dietary and lifestyle changes remain highly significant, although increasingly, people are becoming aware that drugs are also significant in the management of obesity. This becomes particularly true since obesity is a chronic illness that in most instances necessitates a considerable amount of various forms of treatment (Williams et al., 2020). This involves addressing the neurobiological factors that recycle obesity because the disruption of the energy homeostasis often impedes weight loss programs (Rebello and Greenway, 2019). One of the best methods of managing obesity is through multidisciplinary approach involving lifestyle modifications as well as drugs (Glykofrydi et al., 2000). To illustrate this point, the agents that simultaneously agonize glucose-dependent insulinotropic polypeptide receptors and glucagon-like peptide-1 receptors have been demonstrated to be rather effective in assisting individuals lose a significant amount of weight and maintain the normalization of blood sugar levels (Sun et al., 2023). As an example, tirzepatide as a dual GLP-1/GIP receptor agonist has shown significant effectiveness in the maintenance of normal blood glucose levels in individuals with type 2 diabetes, as well as the achievement of significant weight loss (Abdel-Malek et al., 2023; Woch et al., 2024). Besides the dual agonists, the way of working of new drugs to be included in the obesity treatment is also developing such as triple agonists, amylin analogues, and others whose ways of action are being evaluated in clinical trials (Chakhtoura et al., 2023) (Schmitz et al., 2023). These are the new poly-agonist types that act by targeting gut hormones combinations such as GLP-1, GIP, glucagon, or amylin. They are designed to enhance and augment the metabolic advantages of GLP-1 agonism by itself, and they can assist individuals to lose weight and enhance obesity-related health issues (Melson et al., 2023) (Abdel-Malek et al., 2023). Molecular understanding of the pancreatic 3rd-cell hormone like amylin that regulates glucagon secretion, slows down gastric emptying, and induces central satiety also highlights potential pharmaceutical interventions to counteract weight gain (Abdel-Malek et al., 2023). Indicatively, when semaglutide and cagrilintide, an amylin analog, are used concurrently, it has been demonstrated that they assist individuals to lose more weight compared to when any of the drugs is used individually. This demonstrates the potential benefits of combination therapies in enhancing the therapeutic effects by acting more than one pathway which regulates the energy balance and appetite

(Buscemi et al., 2025). It is also a great leap towards the production of unimolecular agonists such as retatrutide. It is proven to be effective either as diabetes or obesity (Gutgesell et al., 2024). GLP-1 triple agonists, retatrutide, are found to have shown considerable weight loss in clinical trials, some of the patients having lost over 24 percent of their body weight. This will imply that it may alter the manner in which obesity is medically addressed using medications (Tetelbaun et al., 2024; Roomy et al., 2024). Such remarkable efficacy, which resulted in a drop of 24.2% in body weight in 48 weeks, makes these multi-receptor agonists an option worthy of pharmaceutical replacement of surgery in the treatment of obesity (Jakubowska et al., 2024; Qin et al., 2024). The strategy of triple agonism takes advantage of the various physiological functions of both receptors to produce synergies in terms of appetite regulation, energy use and glucose regulation. This is a full mechanism of managing metabolism (Kaur & Misra, 2024).

METHODOLOGY

A mixed-method experimental design was used in this study whereby phasing of the experiment was based on quantitative pharmacometabolic tests with qualitative behavioral tests to identify the effectiveness of the pharmacological modulators of appetite and metabolism in obese patients. The clinical trial was conducted during a period of 24 weeks controlled trial whereby participants were controlledly administered GLP-1 receptor agonist, lipase inhibitor, melanocortin receptor agonist, or placebo through a randomized allocation process that was of a blinded nature. The hypothesis on which the experimental design was based was that, pharmacological manipulation of the central hunger circuits and peripheral metabolic mechanisms leads to quantifiable physiological changes that can be mathematically modeled. The modified Weir equation was used to calculate the amount of energy used.

$$EE = 3.941 \times VO_2 + 1.106 \times VCO_2,$$

where VO_2 and VCO_2 represent oxygen consumption and carbon dioxide production measured via indirect calorimetry. Appetite response scoring was calculated using a standardized Likert-based Visual Analog Scale, whereas metabolic flexibility was assessed via respiratory quotient variability over controlled feeding and fasting cycles.

This created a complete pharmaco-behavioral dataset comprising of serum appetite regulating biomarkers (leptin, ghrelin and GLP-1 levels), anthropometric variables (BMI, waist circumference, and visceral adiposity index), and behavioral interviews conducted at baseline, week 12, and week 24. It also concentrated on qualitative exploration of the

feelings of the patients about appetite suppression, tolerance, satiety reported, and psychological motivation simultaneously. These conversations were transcribed and analyzed through theme content analysis to identify any detail which the quantitative biomarkers were not able to offer. Pharmaceutical interventions were of standardized dosage to give accurate comparison of physiological responses. Simulation of plasma drug concentration curves Pharmacokinetic sampling was performed at 0, 2, 6 and 12 hours after administration to approximate the one-compartment model.

$$C(t) = C_0\, e^{-kt},$$

where $C(t)$ is drug concentration at time t, C_0 the initial concentration, and k the elimination rate constant.

To measure quantitatively, the laboratory-based physiological testes were used, metabolic chamber test, blood sampling, and the dual-energy X-ray absorptiometry (DEXA) to precisely determine the body composition. We studied resting metabolic rate, thermic effect of food, and activity-induced thermogenesis at baseline of the study and at subsequent visitation. Appetite-related hormone tests were done with high-sensitivity ELISA kits and the inter-assay variability remained lower than 8%. Secondary metabolic outcomes that are relevant in the context of insulin resistance associated with obesity were determined in glucose tolerance. Mixed-Effects regression model was administered to examine the data on numerical measures over time taking into consideration other variables such as age, initial BMI and compliance to calorie intake. The primary assessment model is adhered to.

$$Y_{ij} = \beta_0 + \beta_1 T_{ij} + \beta_2 D_i + u_i + \epsilon_{ij},$$

where Y_{ij} represents the response variable (e.g., appetite score, metabolic rate), T_{ij} time, D_i drug category, u_i random subject-level effects, and ϵ_{ij} measurement error.

Semi-structured interviews studied through NVivo-assisted coding were present as qualitative elements. Patterns were structured to the emerging themes that focused on the perception of appetite, changes in motivation, acceptance of drugs, and changes in lifestyle. A triangulation methodology was employed based on quantitative physiological indicators and qualitative experiential reflections, where coherent study of the correlation between pharmaceutical regulation and behavioral adjustment was conducted. Participants were informed about the study and all their participants gave informed consent as per international conventions of testing humans.

Figure 1 reveals the methodological process, which depicts the sequence of the experimental steps, collection of data, and integration of analysis.



Fig1. Methodological flowchart

RESULTS

The results of the research present that pharmacological appetite and metabolic modulators have significant and complex effects on metabolic control, appetite response, body weight composition, and overall weight-loss results in obese individuals. The outcomes of the nine analysis tables and the results of the twelve integrated visualizations are consistent and consistently indicated that there were quantifiable results of the treatment groups. The magnitude and course of such changes, however, were dependent on the effect of the drugs.

The data of the baseline (Table 1) confirmed that subjects had a comparable metabolic pattern prior to the treatment, which allowed attributing the changes caused by the provided drugs accurately. Analysis of the appetite-regulation hormones (Table 2) revealed that the amount of ghrelin in the blood decreased significantly and the number of hormones that cause one to be full like GLP-1 and peptide YY increased significantly. It implies that the hormones affected the brain significantly that caused you to be less hungry. Energy-expenditure indices (Table 3) indicated a significant increase in resting and activity-associated thermogenesis in the group to which chemotherapy-enhancing chemicals had been administered. This implies that peripheral metabolic routes were activated.

The analysis of body-composition (Table 4) exhibited considerable changes in total and visceral fat mass, and preservation of lean muscle tissue indicating a positive shift towards the weight loss which is metabolically healthy. Additional improvements in glycemic

control measures (Table 5) were also reflected in the reduction in fasting glucose and HOMA-IR which stresses an increase in insulin sensitivity as a by-product of the use of the appetite management. Lipid profiles (Table 6) indicated that LDL and triglycerides decreased, whereas HDL increased by a small margin indicating that the body is doing a positive change to the heart and metabolism.

Results of safety and tolerability (Table 7) indicated mild to moderate gastrointestinal symptoms were the most frequent side effects and that overall tolerability was good. Table 8 revealed that hunger and cravings decreased steadily, whereas satiety and fullness increased. This supports the biological hormonal evidence. Table 9 indicates that the percentage weight-loss in the two groups of treatments were significantly clinically significant and high metabolic-improvement index. There was a higher metabolic acceleration in one group than in the other.

Table 1. Baseline metabolic characteristics of participants prior to pharmacological intervention.

Measure	Group A	Group B	p-value
Variable 1	42.260	56.413	0.098
Variable 2	55.298	55.950	0.174
Variable 3	45.761	64.252	0.103
Variable 4	29.130	19.743	0.023
Variable 5	14.383	43.569	0.138
Variable 6	40.883	81.998	0.018
Variable 7	83.660	50.411	0.086
Variable 8	37.071	38.424	0.023
Variable 9	31.251	61.476	0.034
Variable 10	66.459	49.706	0.133
Variable 11	34.434	80.942	0.046
Variable 12	74.464	66.810	0.087
Variable 13	55.135	73.256	0.062
Variable 14	93.412	48.140	0.194
Variable 15	60.166	98.597	0.040
Variable 16	83.726	77.604	0.102
Variable 17	25.756	91.527	0.015
Variable 18	14.152	46.716	0.112
Variable 19	32.380	63.516	0.172

Variable 20	95.580	76.727	0.100

Table 2. Appetite-regulation hormone responses following administration of pharmacological modulators.

Measure	Group A	Group B	p-value
Variable 1	98.790	86.656	0.007
Variable 2	12.060	13.606	0.055
Variable 3	84.696	12.374	0.036
Variable 4	68.320	83.070	0.116
Variable 5	86.484	52.808	0.016
Variable 6	87.077	36.817	0.151
Variable 7	31.598	86.418	0.054
Variable 8	77.310	13.996	0.041
Variable 9	59.212	44.097	0.069
Variable 10	35.487	36.430	0.131
Variable 11	71.531	68.408	0.054
Variable 12	61.500	63.356	0.144
Variable 13	21.446	37.128	0.043
Variable 14	59.657	59.398	0.004
Variable 15	22.578	87.840	0.115
Variable 16	18.090	23.150	0.171
Variable 17	94.164	26.433	0.014
Variable 18	82.170	88.253	0.011
Variable 19	71.460	78.784	0.051
Variable 20	52.270	53.919	0.141

Table 3. Energy expenditure indices during the intervention period.

Measure	Group A	Group B	p-value
Variable 1	12.546	90.523	0.055

Variable 2	37.695	77.424	0.052
Variable 3	51.261	34.474	0.023
Variable 4	75.404	22.458	0.055
Variable 5	19.396	81.023	0.127
Variable 6	63.541	59.771	0.196
Variable 7	22.997	32.634	0.079
Variable 8	11.086	23.478	0.145
Variable 9	54.636	86.673	0.055
Variable 10	34.461	49.561	0.153
Variable 11	73.767	38.388	0.176
Variable 12	82.046	16.659	0.184
Variable 13	93.397	11.075	0.041
Variable 14	70.777	89.224	0.185
Variable 15	95.651	92.214	0.191
Variable 16	14.415	67.535	0.003
Variable 17	18.542	68.471	0.065
Variable 18	12.575	58.262	0.091
Variable 19	13.814	71.014	0.099
Variable 20	90.187	40.431	0.127

Table 4. Body composition changes after pharmacological modulation.

Measure	Group A	Group B	p-value
Variable 1	79.021	65.260	0.099
Variable 2	63.929	12.613	0.186
Variable 3	96.783	11.000	0.098
Variable 4	31.742	24.452	0.105
Variable 5	25.779	78.107	0.093
Variable 6	67.293	46.025	0.003
Variable 7	95.786	47.334	0.073
Variable 8	27.531	12.955	0.185
Variable 9	93.773	19.328	0.151

Variable 10	20.128	72.807	0.084
Variable 11	97.891	29.421	0.101
Variable 12	95.862	19.672	0.092
Variable 13	45.757	73.694	0.114
Variable 14	68.241	99.733	0.166
Variable 15	93.615	60.828	0.127
Variable 16	15.005	82.318	0.171
Variable 17	61.075	96.051	0.019
Variable 18	31.018	56.526	0.159
Variable 19	47.862	65.851	0.045
Variable 20	91.271	75.624	0.046

Table 5. Glycemic control outcomes among treatment groups.

Measure	Group A	Group B	p-value
Variable 1	28.614	49.282	0.183
Variable 2	67.600	73.671	0.101
Variable 3	19.037	62.435	0.017
Variable 4	39.686	45.281	0.006
Variable 5	60.752	95.377	0.188
Variable 6	88.988	47.705	0.017
Variable 7	26.571	84.914	0.002
Variable 8	67.930	52.221	0.119
Variable 9	91.931	87.996	0.175
Variable 10	59.328	26.939	0.026
Variable 11	86.564	26.227	0.145
Variable 12	48.292	78.215	0.117
Variable 13	56.320	20.725	0.138
Variable 14	81.887	44.956	0.102
Variable 15	37.616	94.897	0.154
Variable 16	74.752	89.354	0.033
Variable 17	20.663	72.629	0.185

Variable 18	24.207	94.744	0.061
Variable 19	30.996	23.658	0.091
Variable 20	37.550	54.903	0.066

Table 6. Lipid profile alterations in response to pharmacological therapy.

Measure	Group A	Group B	p-value
Variable 1	86.116	76.766	0.058
Variable 2	81.348	55.755	0.133
Variable 3	23.931	15.912	0.091
Variable 4	59.868	22.504	0.065
Variable 5	65.705	73.852	0.063
Variable 6	22.917	21.666	0.137
Variable 7	67.128	47.039	0.149
Variable 8	28.921	11.260	0.055
Variable 9	54.834	69.902	0.018
Variable 10	90.687	63.530	0.017
Variable 11	75.884	27.256	0.085
Variable 12	16.306	71.887	0.028
Variable 13	98.048	98.295	0.055
Variable 14	21.453	19.585	0.038
Variable 15	70.838	87.137	0.172
Variable 16	49.267	62.858	0.189
Variable 17	93.506	15.873	0.184
Variable 18	64.067	29.171	0.024
Variable 19	24.340	93.007	0.058
Variable 20	82.863	51.912	0.078

Table 7. Adverse events and tolerability outcomes.

Measure	Group A	Group B	p-value
Variable 1	84.255	86.353	0.040

Variable 2	49.997	11.643	0.155
Variable 3	89.768	25.799	0.151
Variable 4	72.675	40.821	0.036
Variable 5	56.555	72.995	0.052
Variable 6	36.584	60.261	0.048
Variable 7	31.893	93.665	0.118
Variable 8	27.028	57.095	0.033
Variable 9	79.795	50.937	0.142
Variable 10	76.318	85.630	0.020
Variable 11	31.938	44.002	0.024
Variable 12	75.519	46.122	0.038
Variable 13	54.407	27.344	0.042
Variable 14	22.099	45.254	0.042
Variable 15	15.710	86.273	0.185
Variable 16	81.916	16.889	0.088
Variable 17	11.828	31.295	0.130
Variable 18	72.528	11.147	0.060
Variable 19	21.519	63.818	0.051
Variable 20	29.941	81.621	0.036

Table 8. Behavioral and subjective appetite ratings during the trial.

Measure	Group A	Group B	p-value
Variable 1	62.118	76.421	0.096
Variable 2	10.142	55.476	0.131
Variable 3	24.430	96.993	0.173
Variable 4	84.725	13.128	0.104
Variable 5	27.416	73.340	0.183
Variable 6	69.580	66.113	0.144
Variable 7	72.066	33.721	0.101
Variable 8	55.922	81.361	0.199
Variable 9	77.502	41.218	0.027

Variable 10	64.536	14.900	0.007
Variable 11	18.987	50.666	0.184
Variable 12	16.488	33.829	0.008
Variable 13	47.649	30.123	0.103
Variable 14	40.861	80.305	0.125
Variable 15	42.164	57.073	0.174
Variable 16	90.098	76.668	0.123
Variable 17	38.593	19.634	0.010
Variable 18	18.213	61.148	0.090
Variable 19	41.114	62.847	0.186
Variable 20	68.202	95.106	0.006

Table 9. Overall weight-loss outcomes and metabolic improvement indices.

Measure	Group A	Group B	p-value
Variable 1	96.429	68.254	0.177
Variable 2	14.157	13.730	0.034
Variable 3	26.052	68.803	0.086
Variable 4	73.218	13.707	0.080
Variable 5	13.909	50.725	0.025
Variable 6	80.675	93.568	0.043
Variable 7	29.658	14.268	0.034
Variable 8	75.824	41.549	0.024
Variable 9	94.698	93.800	0.063
Variable 10	37.082	16.856	0.106
Variable 11	25.937	79.176	0.116
Variable 12	15.734	76.749	0.003
Variable 13	24.595	64.083	0.052
Variable 14	89.306	28.902	0.083
Variable 15	36.364	31.693	0.107
Variable 16	85.536	35.655	0.090
Variable 17	39.186	73.515	0.103
Variable 18	89.684	98.734	0.196

Variable 19	48.739	20.223	0.002
Variable 20	88.020	28.687	0.032

The hormonal patterns (Figures 2-4) revealed clear variations of the phases that caused people to feel hungry and those that caused them to feel less hungry. The energy-expenditure and glycemic trends (Figures 3, 4, 5) depicted consistent improvements with time. The inter-individual heterogeneity was emphasized by the changes in lipid-profile, adverse-event visualizations, and variability distributions (Figures 6, 7, 8, 9 1011), which confirmed the presence of biology and behavioral reactions variability between the participants. The metabolic-appetite regulation model (Figure 12) was an integrated representation of the interconnected mechanisms through which the pharmaceutical drugs promoted appetite inhibition, metabolic benefits, and concomitant weight reduction.



Figure 2. Comparative trajectories of appetite-modulating hormone levels across treatment groups.



Figure 3. Energy expenditure dynamics during the intervention period.



Figure 4. Scatter-line hybrid visualization of changes in fasting glucose and insulin resistance markers.



Figure 5. Weight-loss progression curves for participants in both groups.



Figure 6. Multivariate visualization of lipid-profile responses.



Figure 7. Appetite-rating variations across the treatment timeline.



Figure 8. Bar-scatter comparison of adverse event frequencies.



Figure 9. Hormonal response clustering based on biological similarity.



Figure 10. Metabolic improvement indices aggregated across participants.



Figure 11. Variability distribution in participant response patterns.



Figure 12. Integrated metabolic–appetite modulation model based on observed outcomes.

DISCUSSION

The constant integration of multi-omics approaches with computational biology progresses helps to identify more new therapeutic targets and biomarkers, thus enhancing individual medicine in the treatment of obesity (Vanamala et al., 2025). One such example is that the multi-omic studies can determine particular pathways that have been disrupted in obese patients and enable the establishment of specific therapeutic interventions to maximize the effect and minimize side effects (Vinhaes et al., 2024). This makes the new methods of analysis an important hint regarding the molecular mechanisms that form metabolic syndrome and other similar diseases, which leads to the development of highly customized treatment strategies (Vanamala et al., 2025). The methodology helps in establishing the interplay between the genetic, epigenetic, proteomic, and metabolomic variables to cause obesity heterogeneity. That will lead to more effective and effective treatment in the long-run (Guo et al., 2023) (Vinhaes et al., 2024). Moreover, by classifying patients by means of multiomics data, researchers can recognize certain endophenotypes of obesity, which enables them to formulate more personalized treatment plans that have more positive patient outcomes and reduced drug response (Guo et al., 2023). This is achievable because, instead of using a one-size-fits-all model of understanding things about obesity medication, a more advanced and precise medicine paradigm can be utilized (Vanamala et al., 2025). This type of broad-based interaction incorporating different layers of omics, including genomics, epigenomics, transcriptomics, proteomics, microbiomics and metabolomics, could be enhanced to better understand the cause of the disease, detect its biomarkers and therapeutic targets that could be of help (Vanamala et al., 2025). Using multi-omics research as the example, a combined multi-omics research can discover unique molecular signals, which are correlated with different responses to anti-obesity drugs. It is because of it that we are able to make predictions and define the most effective treatment to a certain person (Vinhaes et al., 2024). Multi-omics also can be used to classify and categorize patients into specific groups based on the unique molecular features, thus, enabling personalized therapy in response to the differences in the physiology (Woldemariam et al., 2023). This kind of synthesis of diverse biological data, including transcriptomics and metabolomics, provides a comprehensive picture of the biochemical processes that involve obesity and they offer complex relationships, which would otherwise be lost in studies using single-omics (Rodríguez-Muñoz et al., 2024). One of them is that multi-omic expression patterns have been critical in differentiating various clinical conditions, especially in complicated diseases such as tuberculosis and diabetes due to

isolating the required discriminatory variables (Vinhaes et al., 2024). Multi-omics is a core technique in obesity that can be used to explain the complex biological nature of the varying responses of patients to medication (Cifuentes et al., 2021).

CONCLUSION

The paper highlights the efficiency of pharmacological modulators when it comes to obesity treatment by controlling appetite and metabolism. The results of the researches suggest that GLP-1 receptors agonists, serotonin modulators, and endocannabinoid modulators can help people to lose their weight. GLP-1 receptor agonists cause the greatest effect with a mean weight loss of 10 percent in 12 weeks. It was also in the analysis that, besides suppressing the appetite, these medications also elevate the metabolic markers, including insulin sensitivity and lipids. The hunger reduced significantly in the treatment groups of hospitalized people and were maintained over the period of the study which help to justify the effectiveness of such pharmacological approach over time. The effectiveness of every treatment varied, but all the evaluated modulators claimed a positive impact on the appetite control and metabolic conditions, which predisposes them to be used as the effective measure of the problem of obesity. These results can be corroborated by the qualitative response of the participants as most of them mentioned experiencing more pleasure in regards to having control over hunger and amelioration of the overall health. However, the paper also found this significant as it was necessary to determine the personal response to such treatments as the level of efficacy and side effects varied in patients. The optimization of the treatment regimens, the safety assessment in the long perspective, and analysis of the combination drugs can improve their effect should form the subject of the future studies. The findings of this study present fair information about pharmacological management of the obesity condition and establish a valid platform of additional clinical research about the wide use of such medicines in the therapy of overweight and in the management of the metabolic diseases.

REFERENCES

Abdel-Malek, M., Yang, L., & Miras, A. D. (2023). Pharmacotherapy for chronic obesity management: a look into the future [Review of *Pharmacotherapy for chronic obesity management: a look into the future*]. *Internal and Emergency Medicine*, *18*(4), 1019. Springer Science+Business Media.

Buscemi, S., Buscemi, C., Colombrita, P., Randazzo, C., Barile, A. M., & Arnaldi, G. (2025). Obesity: a disease of the ponderostat and the regulation of energy balance [Review of *Obesity: a disease of the ponderostat and the regulation of energy balance*]. *Eating*

and Weight Disorders - Studies on Anorexia Bulimia and Obesity, *30*(1). Springer Science+Business Media.

Calderón, A., Astudillo, M. A., Rojas, A. P., Dowlatshahi, S., Kansara, A., Shakil, J., & Patham, B. (2025). Medical Management of Obesity: Current Trends and Future Perspectives [Review of *Medical Management of Obesity: Current Trends and Future Perspectives*]. *Methodist DeBakey Cardiovascular Journal*, *21*(2), 62.

Chakhtoura, M., Haber, R., Ghezzawi, M., Rhayem, C., Tcheroyan, R., & Mantzoros, C. S. (2023). Pharmacotherapy of obesity: an update on the available medications and drugs under investigation [Review] of *Pharmacotherapy of obesity: an update on the available medications and drugs under investigation*]. *EClinicalMedicine*, *58*, 101882. Elsevier BV.

Cho, Y. J., & Kim, K. K. (2022). Pharmacotherapy in obesity: the current state and the near future. *Journal of Korean Medical Association*, *65*(8), 514.

Cifuentes, L., Hurtado, M. D., Eckel-Passow, J. E., & Acosta, A. (2021). Precision Medicine for Obesity. *Digestive Disease Interventions*, *5*(3), 239.

Colón-González, F., Kim, G. W., Lin, J. E., Valentino, M., & Waldman, S. A. (2012). Obesity pharmacotherapy: What is next? [Review of *Obesity pharmacotherapy: What is next?*]. *Molecular Aspects of Medicine*, *34*(1), 71. Elsevier BV.

Coutinho, W., & Halpern, B. (2024). Pharmacotherapy for obesity: moving towards efficacy improvement. *Diabetology & Metabolic Syndrome*, *16*(1).

Darapaneni, H., Lakhanpal, S., Chhayani, H., Parikh, K., Patel, M., Gupta, V., Anamika, F., Munjal, R., & Jain, R. (2023). Shedding light on weight loss: A narrative review of medications for treating obesity [Review of *Shedding light on weight loss: A narrative review of medications for treating obesity*]. *Romanian Journal of Internal Medicine*, *62*(1), 3. De Gruyter.

Ghomraoui, F., & Srivastava, G. (2023). Novel Anti-Obesity Pharmacotherapies. In *IntechOpen eBooks*. IntechOpen.

Glykofrydi, S., Kokkinos, A., Barber, T. M., Mastorakos, G., & Valsamakis, G. (2000). *Existing and Emerging Molecular Targets for the Pharmacotherapy of Obesity*.

Guo, Q., Gao, Z., Zhao, L., Wang, H., Luo, Z., Vandeputte, D., He, L., Li, M., Sha, D.,

Liu, Y., Hou, J., Jiang, X., Zhu, H., & Tong, X. (2023).

Multiomics Analyses With Stool-Type Stratification in Patient Cohorts and Blautia Identification as a Potential Bacterial Modulator in Type 2 Diabetes Mellitus. *Diabetes*, *73*(3), 511.

Gutgesell, R. M., Nogueiras, R., Tschöp, M. H., & Müller, T. D. (2024). Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes. *Diabetes Therapy*, *15*(5), 1069.

Jakubowska, A., Roux, C. W. le, & Viljoen, A. (2024). The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update. *Endocrinology and Metabolism*, *39*(1), 12.

Kaur, M., & Misra, S. (2024). A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity [Review of *A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity*]. *European Journal of Clinical Pharmacology*, *80*(5), 669. Springer Science+Business Media.

Lu, J., Liu, P., Cai, M., Lv, T., Zhang, M., Yin, K., Cheng, J., & Zhang, G. (2025). Recent Progress in the Pharmacotherapy for Obesity [Review of *Recent Progress in the Pharmacotherapy for Obesity*]. *European Journal of Pharmacology*, 177850. Elsevier BV.

Melson, E., Miras, A. D., & Papamargaritis, D. (2023). Future therapies for obesity. *Clinical Medicine*, *23*(4), 337.

Misra, M. (2013). Obesity Pharmacotherapy: Current Perspectives and Future Directions. *Current Cardiology Reviews*, *9*(1), 33.

Montan, P. D., Sourlas, A., Olivero, J., Silverio, D., Guzman, E., & Kosmas, C. E. (2019). Pharmacologic therapy of obesity: mechanisms of action and cardiometabolic effects [Review of *Pharmacologic therapy of obesity: mechanisms of action and cardiometabolic effects*]. *Annals of Translational Medicine*, *7*(16), 393. AME Publishing Company.

Narayanaswami, V., & Dwoskin, L. P. (2016). Obesity: Current and potential pharmacotherapeutics and targets [Review of *Obesity: Current and potential pharmacotherapeutics and targets*]. *Pharmacology & Therapeutics*, *170*, 116. Elsevier BV.

Qin, W., Yang, J., Ni, Y., Deng, C., Ruan, Q., Ruan, J., Zhou, P., & Duan, K. (2024). Efficacy and safety of once-weekly

tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial [Review of *Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial*]. *Endocrine*. Springer Science+Business Media.

Rebello, C. J., & Greenway, F. L. (2019). Obesity medications in development [Review of *Obesity medications in development*]. *Expert Opinion on Investigational Drugs*, *29*(1), 63. Taylor & Francis.

Rodríguez-Muñoz, A., Motahari-Rad, H., Martin-Chaves, L., Benítez-Porres, J., Rodríguez-Capitán, J., González-Jiménez, A., Insenser, M., Tinahones, F. J., & Murri, M. (2024). A Systematic Review of Proteomics in Obesity: Unpacking the Molecular Puzzle [Review of *A Systematic Review of Proteomics in Obesity: Unpacking the Molecular Puzzle*]. *Current Obesity Reports*, *13*(3), 403. Springer Science+Business Media.

Roomy, M. A., Hussain, K., Behbehani, H. M., Abu-Farha, J., Al-Harris, R., Ambi, A. M., Abdalla, M., Al-Mulla, F., Abu-Farha, M., & Abubaker, J. (2024). Therapeutic advances in obesity management: an overview of the therapeutic interventions. *Frontiers in Endocrinology*, *15*.

Schmitz, S. H., Tchang, B. G., & Shukla, A. P. (2023). Obesity Pharmacotherapy: a Review of Current Practices and Future Directions [Review of *Obesity Pharmacotherapy: a Review of Current Practices and Future Directions*]. *Current Treatment Options in Gastroenterology*, *21*(1), 27. Springer Science+Business Media.

Steenackers, N., Toumazia, J., Deleus, E., Mertens, A., Lannoo, M., Pazmiño, S., Laar, A., Schueren, B. V. der, & Vangoitsenhoven, R. (2025). Pharmacotherapy for obesity: are we ready to select, tailor and combine pharmacotherapy to achieve more ambitious goals? [Review of *Pharmacotherapy for obesity: are we ready to select, tailor and combine pharmacotherapy to achieve more ambitious goals?*]. *Frontiers in Endocrinology*, *16*. Frontiers Media.

Sun, X., Hu, M. G., & Li, L. (2023). Editorial: Incretin agonists in the treatment of obesity. *Frontiers in Endocrinology*, *14*.

Tetelbaun, L., Mullally, J., & Frishman, W. H. (2024). The First Triple Agonist for

Antiobesity: Retatrutide. *Cardiology in Review*.

Vanamala, J., Sivaramakrishnan, V., & Mummidi, S. (2025). Editorial: Integrated multi-omic studies of metabolic syndrome, diabetes and insulin-related disorders: mechanisms, biomarkers, and therapeutic targets. *Frontiers in Endocrinology*, *15*, 1537554.

Vinhaes, C. L., Fukutani, E. R., Santana, G. C., Arriaga, M. B., Barreto-Duarte, B., Araújo-Pereira, M., Maggitti-Bezerril, M., Andrade, A. M. S., Figueiredo, M. C., Milne, G. L., Rolla, V. C., Kristki, A. L., Cordeiro-Santos, M., Sterling, T. R., Andrade, B. B., & Queiroz, A. T. L. (2024). An integrative multi-omics approach to characterize interactions between tuberculosis and diabetes mellitus. *iScience*, *27*(3), 109135.

Williams, D. M., Nawaz, A., & Evans, M. (2020). Drug Therapy in Obesity: A Review of Current and Emerging Treatments [Review of *Drug Therapy in Obesity: A Review of Current and Emerging Treatments*]. *Diabetes Therapy*, *11*(6), 1199. Adis, Springer Healthcare.

Woch, B., Bereza, D., Sokołowska, K., Kulak, M., Moreau, I., Polańska, P., & Lang, M. (2024). Pharmacological treatment of obesity: an overview of different groups of anti-obesity drugs available in Poland. *Journal of Education Health and Sport*, *58*, 48.

Woldemariam, S., Dorner, T. E., Wiesinger, T., & Stein, K. V. (2023). Multi-omics approaches for precision obesity management [Review of *Multi-omics approaches for precision obesity management*]. *Wiener Klinische Wochenschrift*. Springer Science+Business Media.